Abstract
Tumor cells often have defects in DNA repair pathways that make them vulnerable to specific DNA-damaging anticancer agents. The identification of DNA repair defects in tumor cells and the evaluation of their influence on the cytotoxicity of anticancer drugs are active areas of scientific investigation that may help rationalize and improve cancer chemotherapy. This article reviews the available data on the influence of defects in proteins involved in the major DNA repair pathways (i.e., homologous recombination, non-homologous end joining, base excision repair, nucleotide excision repair, mismatch repair, Fanconi anemia repair, translesion synthesis and direct reversal repair) on the cytotoxicity of the FDAapproved anticancer drugs. It is shown that specific deficiencies in these DNA repair pathways alter the cytotoxicity of 60 anticancer drugs, including classical DNA-targeting drugs (e.g., alkylating agents, cytotoxic antibiotics, DNA topoisomerase inhibitors and antimetabolites) and other drugs whose primary pharmacological target is not the DNA (e.g., antimitotic agents, hormonal and targeted therapies). This information may help predict response to anticancer drugs in patients with tumors having specific DNA repair defects.
Keywords: Anticancer, chemotherapy, DNA damage, DNA damage response.
Current Medicinal Chemistry
Title:Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Volume: 21 Issue: 30
Author(s): Jose Manuel Calderon-Montano, Estefania Burgos-Moron, Manuel Luis Orta and Miguel Lopez-Lazaro
Affiliation:
Keywords: Anticancer, chemotherapy, DNA damage, DNA damage response.
Abstract: Tumor cells often have defects in DNA repair pathways that make them vulnerable to specific DNA-damaging anticancer agents. The identification of DNA repair defects in tumor cells and the evaluation of their influence on the cytotoxicity of anticancer drugs are active areas of scientific investigation that may help rationalize and improve cancer chemotherapy. This article reviews the available data on the influence of defects in proteins involved in the major DNA repair pathways (i.e., homologous recombination, non-homologous end joining, base excision repair, nucleotide excision repair, mismatch repair, Fanconi anemia repair, translesion synthesis and direct reversal repair) on the cytotoxicity of the FDAapproved anticancer drugs. It is shown that specific deficiencies in these DNA repair pathways alter the cytotoxicity of 60 anticancer drugs, including classical DNA-targeting drugs (e.g., alkylating agents, cytotoxic antibiotics, DNA topoisomerase inhibitors and antimetabolites) and other drugs whose primary pharmacological target is not the DNA (e.g., antimitotic agents, hormonal and targeted therapies). This information may help predict response to anticancer drugs in patients with tumors having specific DNA repair defects.
Export Options
About this article
Cite this article as:
Calderon-Montano Manuel Jose, Burgos-Moron Estefania, Orta Luis Manuel and Lopez-Lazaro Miguel, Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review, Current Medicinal Chemistry 2014; 21(30) . https://dx.doi.org/10.2174/0929867321666140601203816
DOI https://dx.doi.org/10.2174/0929867321666140601203816 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Synthesis, Characterization and In Vitro Evaluation of Self-Assembled poly(ethylene glycol)-glycyrrhetinic Acid Conjugates
Letters in Organic Chemistry The Renin-Angiotensin System: New Insight into Old Therapies
Current Medicinal Chemistry Non-coding RNAs in Exosomes: New Players in Cancer Biology
Current Genomics Polymer Structures for Sensors and Actuators 1. Analyte Biosensor
Recent Patents on Materials Science Aberrant Expression of MicroRNAs in B-cell Lymphomas
MicroRNA TWIST1 Gene: First Insights in Felis catus
Current Genomics Imaging Virus-Associated Cancer
Current Pharmaceutical Design Anticancer Activities of New N-hetaryl-2-cyanoacetamide Derivatives Incorporating 4,5,6,7-Tetrahydrobenzo[b]thiophene Moiety
Anti-Cancer Agents in Medicinal Chemistry A synopsis on the linkage between age-related dementias and vascular disorders
CNS & Neurological Disorders - Drug Targets Multi-target Activities of Selected Alkaloids and Terpenoids
Mini-Reviews in Organic Chemistry Curcumin - Properties, Applications and Modification of Structure
Mini-Reviews in Organic Chemistry Advances in Drug Safety
Current Pharmaceutical Design The Roles of Chromatin Remodeling Proteins in Cancer
Current Protein & Peptide Science In-vitro Antioxidant activity of ‘Aswathy Chooranam’- a Siddha Drug
Current Traditional Medicine Vascular Disrupting Agents (VDAs) in Anticancer Therapy
Current Clinical Pharmacology The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
Current Topics in Medicinal Chemistry DIMming Ovarian Cancer Growth
Current Drug Targets Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors
Current Topics in Medicinal Chemistry HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design